Currently, there are 208.22M common shares owned by the public and among those 198.84M shares have been available to trade.
The company’s stock has a 5-day price change of 15.58% and 101.74% over the past three months. SGMO shares are trading 70.66% year to date (YTD), with the 12-month market performance up to 87.31% higher. It has a 12-month low price of $0.29 and touched a high of $1.48 over the same period. SGMO has an average intraday trading volume of 13.97 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.03%, 8.21%, and 37.86% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Sangamo Therapeutics Inc (NASDAQ: SGMO) shares accounts for 41.90% of the company’s 208.22M shares outstanding.
It has a market capitalization of $193.06M and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$1.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.21% over the week and 8.56% over the month.
Earnings per share for the fiscal year are expected to increase by 68.83%, and 50.55% over the next financial year.
Looking at the support for the SGMO, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on November 03, 2023, with the firm’s price target at $6-$2. BofA Securities coverage for the Sangamo Therapeutics Inc (SGMO) stock in a research note released on April 28, 2023 offered a Underperform rating with a price target of $1.50. Wedbush was of a view on February 27, 2023 that the stock is Outperform, while BofA Securities gave the stock Neutral rating on January 06, 2023, issuing a price target of $8- $5. Wedbush on their part issued Neutral rating on June 13, 2022.
